Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.46 |
| ▸ | TACR2 | P21452 | 2/20 | 0.46 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | JAK1 | P23458 | 1/20 | 0.44 |
| ▸ | TYK2 | P29597 | 1/20 | 0.44 |
| ▸ | JAK3 | P52333 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.43 |
| ▸ | UBE2N | P61088 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3983700 | 0.96 | LMNA (0.48) | ALDH1A1SERPINE1MAPK1JAK2JAK1 | |
| SCHEMBL4618697 | 0.92 | ALDH1A1 (0.45) | ALDH1A1KDM4EPKMSERPINE1TACR2 | |
| SCHEMBL3983571 | 0.89 | SERPINE1 (0.45) | ALDH1A1KDM4EPKMSERPINE1TACR2 | |
| SCHEMBL3948275 | 0.85 | ALDH1A1 (0.48) | ALDH1A1KDM4EPKMSERPINE1TACR2 | |
| SCHEMBL3982665 | 0.85 | SERPINE1 (0.47) | ALDH1A1SERPINE1HIF1AMAPT | |
| SCHEMBL4087564 | 0.84 | SERPINE1 (0.51) | ALDH1A1SERPINE1HIF1AMAPTCA1 | |
| SCHEMBL3981129 | 0.84 | SERPINE1 (0.46) | ALDH1A1SERPINE1TACR2MAPK1RAB9A | |
| SCHEMBL3982480 | 0.84 | SERPINE1 (0.51) | ALDH1A1SERPINE1HIF1AMAPT | |
| SCHEMBL3982591 | 0.83 | SERPINE1 (0.50) | ALDH1A1KDM4EPKMSERPINE1BDKRB1 | |
| SCHEMBL3989040 | 0.83 | SERPINE1 (0.46) | ALDH1A1SERPINE1HIF1ASMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1888058-B1 | INHIBITORS OF SOLUBLE ADENYLATE CYCLASE | BAYER SCHERING PHARMA AG (DE) | 2009-05-20 | — | — | EP | claimed |
| US-7417066-B2 | Inhibitors of soluble adenylate cyclase | SCHERING AG (DE) | 2008-08-26 | — | — | US | claimed |
| US-20060281744-A1 | Inhibitors of soluble adenylate cyclase | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-12-14 | — | — | US | claimed |
| EP-1888058-B1 | INHIBITORS OF SOLUBLE ADENYLATE CYCLASE | BAYER SCHERING PHARMA AG (DE) | 2009-05-20 | — | — | EP | disclosed |
| US-7417066-B2 | Inhibitors of soluble adenylate cyclase | SCHERING AG (DE) | 2008-08-26 | — | — | US | disclosed |
| US-7417066-B2 | Inhibitors of soluble adenylate cyclase | SCHERING AG (DE) | 2008-08-26 | — | — | US | disclosed |
| US-7417066-B2 | Inhibitors of soluble adenylate cyclase | SCHERING AG (DE) | 2008-08-26 | — | — | US | disclosed |
| EP-1888058-A2 | INHIBITORS OF SOLUBLE ADENYLATE CYCLASE | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006131398-A2 | INHIBITORS OF SOLUBLE ADENYLATE CYCLASE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-12-14 | — | — | WO | disclosed |
| US-20060281744-A1 | Inhibitors of soluble adenylate cyclase | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281744-A1 | Inhibitors of soluble adenylate cyclase | ADCY1, ADCY2, ADCY5 | ALDH1A1 262/4885KDM4E 4160/4885PKM 2673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.